Patents by Inventor Ruth Ross

Ruth Ross has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11551790
    Abstract: In some embodiments, a system includes an ingestible signal generator coupled to a medication and configured to generate a body-transmissible signal upon ingestion by a user. The system also includes a receiver, the receiver including a sensor configured to detect the body-transmissible signal, the receiver configured to generate and wirelessly transmit a sensor signal based on the body-transmissible signal. The system also includes a user device. A processor of the user device is configured to wirelessly monitor the sensor for the sensor signal and, in response to not receiving the sensor signal within a predetermined time period, generate a notification. The processor is further configured to send a signal to present the notification and receive a response to the notification from the user. The processor is also configured to identify at least one trend associated with the sensor signal and the medication, and perform an action based thereon.
    Type: Grant
    Filed: August 10, 2017
    Date of Patent: January 10, 2023
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: John P. Docherty, Ainslie Hatch, Ruth Ross, Dawn I. Velligan, Peter Weiden
  • Publication number: 20220257569
    Abstract: The present application pertains to methods of using indole-oxadiazole compounds of Formula I to modulate cannabinoid receptor activity: I In particular diseases, disorders or conditions that benefit from modulating cannabinoid receptor activity, such as non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), schizophrenia, bipolar disorder, psychosis, metabolic syndrome, type-2 diabetes, dyslipidaemia, obesity, eating disorders, cardiovascular diseases and disorders, and other conditions as described herein, may be treated. Also included in the present application are certain novel compounds of Formula Ia and pharmaceutical compositions comprising these compounds.
    Type: Application
    Filed: September 12, 2019
    Publication date: August 18, 2022
    Applicants: THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO, THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN
    Inventors: Iain Robert GREIG, Ruth ROSS, Amy RAMSEY, Catherine MIELNIK, Laurent Alain Claude TREMBLEAU, Mostafa Hamed ABDELRAHMAN
  • Patent number: 10435412
    Abstract: The present invention relates to a family of chromenopyrazole derivatives of formula (I): which have the ability to modulate the receptor of the cannabinoid family GPR55, whereby the invention also relates to the use of these compounds for the manufacture of a medicament for the treatment of diseases in which the GPR55 receptor has a physiological role such as diabetes, Parkinson's disease, multiple sclerosis, neuropathic pain, osteoporosis and cancers such as cholangiocarcinoma, breast cancer, ovarian and prostate cancer, glioblastoma, and cutaneous carcinoma.
    Type: Grant
    Filed: April 27, 2016
    Date of Patent: October 8, 2019
    Assignees: THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO, CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)
    Inventors: Nadine Jagerovic, Paula Morales Lazaro, Ruth Ross, Lauren Whyte
  • Patent number: 10377711
    Abstract: The present disclosure relates to indole derivatives of the formula (I) which are cannabinoid type 1 receptor modulators and which are useful in the treatment of diseases in which modulation of the receptor is beneficial; to processes for their preparation; to pharmaceutical compositions comprising them; and to methods of using them.
    Type: Grant
    Filed: August 26, 2015
    Date of Patent: August 13, 2019
    Assignees: The University Court of the University of Aberdeen, The Governing Council of the University of Toronto
    Inventors: Ruth Ross, Iain Greig, Matteo Zanda, Chih-Chung Tseng
  • Publication number: 20180201620
    Abstract: The present invention relates to a family of chromenopyrazole derivatives of formula (I): which have the ability to modulate the receptor of the cannabinoid family GPR55, whereby the invention also relates to the use of these compounds for the manufacture of a medicament for the treatment of diseases in which the GPR55 receptor has a physiological role such as diabetes, Parkinson's disease, multiple sclerosis, neuropathic pain, osteoporosis and cancers such as cholangiocarcinoma, breast cancer, ovarian and prostate cancer, glioblastoma, and cutaneous carcinoma.
    Type: Application
    Filed: April 27, 2016
    Publication date: July 19, 2018
    Inventors: Nadine Jagerovic, Paula Morales Lazaro, Ruth Ross, Lauren Whyte
  • Publication number: 20180118681
    Abstract: The present disclosure relates to indole derivatives of the formula (I) which are cannabinoid type 1 receptor modulators and which are useful in the treatment of diseases in which modulation of the receptor is beneficial; to processes for their preparation; to pharmaceutical compositions comprising them; and to methods of using them.
    Type: Application
    Filed: August 26, 2015
    Publication date: May 3, 2018
    Inventors: Ruth Ross, Iain Greig, Matteo Zanda, Chih-Chung Tseng
  • Publication number: 20170337330
    Abstract: In some embodiments, a system includes an ingestible signal generator coupled to a medication and configured to generate a body-transmissible signal upon ingestion by a user. The system also includes a receiver, the receiver including a sensor configured to detect the body-transmissible signal, the receiver configured to generate and wirelessly transmit a sensor signal based on the body-transmissible signal. The system also includes a user device. A processor of the user device is configured to wirelessly monitor the sensor for the sensor signal and, in response to not receiving the sensor signal within a predetermined time period, generate a notification. The processor is further configured to send a signal to present the notification and receive a response to the notification from the user. The processor is also configured to identify at least one trend associated with the sensor signal and the medication, and perform an action based thereon.
    Type: Application
    Filed: August 10, 2017
    Publication date: November 23, 2017
    Inventors: John P. DOCHERTY, Ainslie HATCH, Ruth ROSS, Dawn I. VELLIGAN, Peter WEIDEN
  • Publication number: 20060172019
    Abstract: The present invention pertains to cannabinoid (CB) receptor inverse agonists and neutral antagonists, and especially CB1 and CB2 inverse agonists and neutral antagonists; such as, for example, certain pyrazole compounds; their use in the inhibition of osteoclasts (for example, the inhibition of the survival, formation, and/or activity of osteoclasts), and/or in the inhibition of bone resorption; their use in connection with treatment of bone disorders, such as conditions mediated by osteoclasts (e.g., increased osteoclast activity) and/or characterised by (e.g., increased) bone resorption, such as osteoporosis (e.g., osteoporosis not associated with inflammation; e.g., osteoporosis associated with a genetic predisposition, sex hormone deficiency, or ageing), cancer associated bone disease, and Paget's disease of bone.
    Type: Application
    Filed: March 2, 2004
    Publication date: August 3, 2006
    Inventors: Stuart Ralston, Ian Greig, Ruth Ross, Aymen Mohamed, Robert Van't Hof